Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
about
Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compoundsAuranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cellsDeubiquitinases in cancer.Auranofin is a potent suppressor of osteosarcoma metastasis.Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia.Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma.Chemical biology of anticancer gold(III) and gold(I) complexes.Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells.Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling.Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.Auranofin: repurposing an old drug for a golden new age.A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers.A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy.Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.Elimination of stem-like cancer cell side-population by auranofin through modulation of ROS and glycolysis.Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug repositionDeubiquitinases as Anticancer Targets of Gold Complexes
P2860
Q28082497-47D844C1-4BFD-40DF-888F-8180E616CADBQ33829292-425409A1-7BB4-44BC-844B-6258C34773C9Q35615675-10FB482E-38CA-49BA-B4AF-BE3DAE4F0E3AQ35955141-EB32EE61-060E-4BF2-B2AC-3610B0C55D55Q36729542-FBEBE3E6-5416-4CAF-BDAD-482955346ED4Q36771950-6CA68EE2-1C66-41CB-A17F-0BE07D2B8FB9Q36841290-E8C2A84C-6DEB-490F-A119-1FCDD0F2C582Q37440054-C462C342-658E-4277-9FE3-189B0702DD82Q37575771-C2495B96-A7A4-4781-9C8A-ED341DCE06FFQ37706134-0DE2249D-48D3-4603-9B1F-8804A39D23F6Q38418786-1EFF94B5-8075-4F77-BB2F-E2E53E9EA589Q38755076-A074664C-6FF6-4EC1-849A-64375BE635CAQ38777221-F207C011-54EB-4E79-8F98-6A8120EC054DQ41335233-DB8A08AD-92DA-410B-9C19-6BFD057E1B73Q41474201-DFAF8137-D6E2-4C7C-B386-78DA26321E5CQ42362660-32D225F0-9E21-4072-B8A4-6380428EC6D6Q43226621-54768AE7-4770-46BB-A3A4-B5CC833DAE55Q47098444-F9A030A4-39E0-4896-A083-819180DA8897Q47446573-A1CDE5AD-FF8B-4E5E-B64B-DD92BE3397B0Q47631097-279C3868-79EF-4DD9-B03B-494447E2B334Q48524331-5B2EF30F-CD96-4624-AEB1-A257954A5CFDQ50240916-03DE5233-4FE1-4FFD-B33D-8324C1FCC871Q52846906-E1175E38-55BC-4A38-BE00-0D322EC28C69Q57163862-54FAE8EB-376C-486B-920F-12204017A770Q58921478-747013E8-CFFF-425E-9563-7FA5C8A40FEE
P2860
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@ast
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@en
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@nl
type
label
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@ast
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@en
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@nl
prefLabel
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@ast
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@en
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@nl
P2093
P2860
P356
P1433
P1476
Anti-rheumatic agent auranofin ...... nt and -independent mechanisms
@en
P2093
Bing Z Carter
Chong Zhao
Hongbiao Huang
Jinbao Liu
Ningning Liu
Q Ping Dou
Quentin Liu
Shouting Liu
Siyan Liao
P2860
P304
P356
10.18632/ONCOTARGET.2361
P407
P50
P577
2014-10-01T00:00:00Z